Clinical Significance of TF and VEGF Expressions on Peripheral CD14 Positive Monocytes in Patients with Diffuse Large B Cell Lymphoma.
10.7534/j.issn.1009-2137.2019.01.011
- Author:
Ya-Jun JIANG
1
;
Gui-Hua ZHU
1
;
Yao HE
1
;
Xing-Xing CHAI
1
;
Xiao-Yun YANG
1
;
Fan-Jing MENG
1
;
Wan-Chuan ZHUANG
2
Author Information
1. Department of Hematology, The Second People's Hospital of Lianyungang, Lianyungang 222006, Jiangsu Province, China.
2. Department of Hematology, The Second People's Hospital of Lianyungang, Lianyungang 222006, Jiangsu Province, China.E-mail: wanchuanzhuang@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Humans;
Lipopolysaccharide Receptors;
Lymphoma, Large B-Cell, Diffuse;
Monocytes;
Prognosis;
Thromboplastin;
Vascular Endothelial Growth Factor A
- From:
Journal of Experimental Hematology
2019;27(1):67-73
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical significance of tissue factor (TF) and vascular endothelial growth factor (VEGF) expression on peripheral blood CD14 positive monocytes in patients with diffuse large B cell lymphoma (DLBCL).
METHODS:The expressions of TF and VEGF on peripheral CD14 monocytes in 41 patients with DLBCL (DLBCL group) before chemotherapy and after 4 chemotherapeutic courses, and in 20 healthy subjects (control group) were detected by flow cytometry respectively, meanwhile, the relationship of the expression of TF and VEGF with international prognostic indexes (IPI) and short-term effects were analysed.
RESULTS:The expression levels of TF and VEGF on peripheral CD14 monocytes in DLBCL group were significantly higher than those in control group (P<0.01), and a positive correlation was found between the two groups (r=0.755, P<0.01). The expression of TF and VEGF on CD14 monocytes in patients with prognostic risk factors significantly increased as compared with those in patients without prognostic risk factors (P<0.05), but there were no significant differences of TF and VEGF expressions on CD14 monocytes in DLBCL group with different sex, age, subtypes (P＞0.05). As compared with patients without prognostic risk factors, the expression levels of TF and VEGF on CD14 monocytes of patients with prognostic risk factors significantly increased (P<0.05). The expression of TF and VEGF on CD14 monocytes in DLBCL group showed an increasing tendency along with the increase of IPI index (P<0.01). The expression levels of TF and VEGF on CD14 monocytes in remission group before chemotherapy were lower than those in non-remission group (P<0.01); after chemotherapy, the expression levels of TF and VEGF on CD14 monocytes in remission group were lower than those before chemotherapy (P<0.05), while the TF and VEGF expression levels in non-remission group were no singnificauly different from TF and VEGF levels before chemtherapy (P>0.05), the survival of patients in group with low expression of TF and VEGF was superior to that in group with high expression of TF and VEGF (P<0.05).
CONCLUSION:The paripheral blood CD14 monocytes in DLBCL patients highly express the TF and VEGF, which relate with IPI, therapeutic efficacy and survival, thus the TF and VEGF expression levels are of reference significance for evaluating the therapeutic efficacy and prognosis of patients.
